As previously reported, Argus analyst Kristina Ruggeri upgraded Cardinal Health to Buy from Hold with a $120 price target. The company is benefiting from its COVID-19 vaccine distribution and strong demand for its generics program amid an uncertain economy and a cautious consumer, having recently reported a Q2 earnings beat, the analyst tells investors in a research note. Argus is raising its FY24 EPS view to $7.14 from $6.79 and also raising its FY25 estimate to $7.72 from $7.50, adding that Cardinal’s struggling Medical segment is also showing signs of recovery, with quarterly revenue growth for the first time since the pandemic.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CAH:
- Neurocrine price target raised to $154 from $150 at Canaccord
- Cardinal Health Board of Directors Approves Quarterly Dividend
- Precipio, Cardinal Health enter distribution agreement for HemeScreen portfolio
- Cardinal Health price target raised to $125 from $122 at UBS
- Cardinal Health price target raised to $109 from $96 at TD Cowen